Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;5(1):46-56.
doi: 10.3978/j.issn.2078-6891.2013.055.

Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases

Akshat Saxena  1 , Terence C Chua  1 , Francis C Chu  1 , Keh Min Ng  1 , Pradyumna Herle  1 , David L Morris  1
Affiliations

Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases

Akshat Saxena et al. J Gastrointest Oncol. 2014 Feb.

Abstract

Background: Ablative strategies have been used to treat and facilitate hepatic resection (HR) in patients with otherwise unresectable colorectal liver metastases (CLM). We evaluated the efficacy of HR, concomitant HR and ablation and isolated ablation on recurrence and survival outcomes after treatment of CLM in patients with 1-4 and ≥5 lesions, respectively.

Methods: A retrospective review of a prospectively collected hepatobiliary surgery database was performed on patients who underwent treatment for isolated CLM between 1990 and 2010. Pre-operative and treatment characteristics were compared between patients who underwent HR, concomitant HR and ablation and ablation alone. The impact of treatment modality on survival and recurrence outcomes was determined.

Results: A total of 701 patients met inclusion criteria; 550 patients (78%) had 1-4 lesions and 151 patients (22%) had ≥5 lesions. Overall median survival for the entire cohort was 35 months with 5- and 10-year survival of 33% and 20%, respectively. Overall median and 5-year recurrence-free survival (RFS) was 13 months and 21%, respectively. For patients with 1-4 lesions, median survival was 37 months with 5-year survival of 36%. Stratified by procedure type, 5-year survival was 41% in patients who underwent HR, 35% in patients who underwent concomitant HR and ablation and 13% in patients who underwent ablation alone (P<0.001). For patients with ≥5 lesions, median survival was 28 months with 5-year survival of 23% without difference between treatment groups (P=0.078).

Conclusions: HR appears to be the most effective strategy for patients with 1-4 lesions. When ≥5 lesions are present, ablative strategies are useful in facilitating HR in otherwise unresectable patients.

Keywords: Colorectal cancer; ablation; hepatectomy; liver metastases; resection; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival after hepatic intervention for colorectal cancer liver metastases (n=701).
Figure 2
Figure 2
Overall survival of patients with 1-4 lesions after hepatic intervention for colorectal cancer liver metastases, stratified by treatment modality (P<0.001).
Figure 3
Figure 3
Overall survival of patients with ≥5 lesions after hepatic intervention for colorectal cancer liver metastases, stratified by treatment modality (P=0.078).
Figure 4
Figure 4
Recurrence-free survival after hepatic intervention for colorectal cancer liver metastases (n=688).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239:722-30; discussion 730-2 - PMC - PubMed
    1. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46 - PubMed
    1. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25; discussion 825-7 - PMC - PubMed
    1. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-22, discussion 722-4 - PMC - PubMed
    1. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-47; discussion 447-50 - PMC - PubMed